Aflibercept
Brand Names: Eylea, Enzeevu, Eylea Hd
Methodology & AI Transparency ⓘ
Aflibercept Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage eylea: is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 16 anonymous logs for Aflibercept (RxNorm 1232154).
- 3 Typical cash cost range: Public pharmacy ledger: $151.87 low cash benchmark vs. $372.08 chain retail average ($3.5400/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Aflibercept): peripheral edema (2.9%), nausea (8.3%), headache (7%).
Ask our AI Specialists anything about Aflibercept
Aflibercept Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage eylea: is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of.
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability.
Systemic exposure to Aflibercept reflects Complete (~100%) parenteral systemic delivery for Aflibercept (2 mg/.05mL Injection, Solution) absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (aflibercept), sustaining receptor engagement across a Biphasic clearance with 5–13 hr terminal t½ under Aflibercept maintenance half-life window (rapid intravascular/parenteral onset within 15–45 minutes after aflibercept administration response profile).
Dosing protocols (2 mg/.05mL Injection, Solution or 8 mg/.07mL Injection, Solution or 40 mg/mL Injection, Solution) balance efficacy (91.00% patient satisfaction across 16 logs) against nausea (8.3% of reports), headache (7% of reports), dizziness (6.1% of reports), with strict avoidance in 4.2 active intraocular inflammation eylea is contraindicated in patients with active intraocular inflammation.; known hypersensitivity to aflibercept or structurally related vascular endothelial growth factor inhibitor compounds.
Avoid overlapping vascular endothelial growth factor inhibitor prescriptions alongside Aflibercept to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Aflibercept; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4.2 Active Intraocular Inflammation EYLEA is contraindicated in patients with active intraocular inflammation.
- Known hypersensitivity to Aflibercept or structurally related vascular endothelial growth factor inhibitor compounds
Logged Side-Effect Incidence (16 Reports)
Aflibercept Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Aflibercept)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Association between screening duration and treatment outcomes in the clinical: What a 1,152-Participant Study Found Linear regression coefficients for screening duration were not statistically significant for BCVA or CST at week 8 (BCVA: B = - 0.058, P = 0.242; CST: B = - 0.050, P = 0.908) or at week 48 (BCVA: B = - 0.015, P = 0.843; CST: B... Scientific reports • 2026-04-02 • Phase III Randomized Trial | N = 1,152 | 90/100 | PMID 41927600 ↗ |
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on Benefits and safety OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS: What a 244-Participant Study Found Proposed biosimilar aflibercept matched reference aflibercept in efficacy, safety, and how the body absorbs the medicine in participants with neovascular age-related macular degeneration. Retina (Philadelphia, Pa.) • 2024-10-01 • Phase III Randomized Trial | N = 244 | 82/100 | PMID 39287533 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, durability, and safety of faricimab with extended dosing up to every 16 Faricimab up to Q16W offered durable vision gains and anatomic improvements up to 2 years in patients with DME in the YOSEMITE Japan subgroup. Japanese journal of ophthalmology • 2024-09-15 • Phase III Randomized Trial | N = 60 | 82/100 | PMID 39083147 ↗ |
| Can This Approach Help? Inside the Latest Research on [New options determining the success of treatment for neovascular age-related Given the proven effectiveness in improving best-corrected visual acuity (BCVA), superior outcomes in resolving intra- and/or subretinal fluid (IRF/SRF), and reduced treatment burden, it appears optimal to broadly transition... Vestnik oftalmologii • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40591387 ↗ |
Aflibercept Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.5400/unit (~$106.20/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $372.08 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $151.87 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Aflibercept Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Aflibercept RxNorm Concept ID | 1232154 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.5400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $372.08 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $151.87 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Aflibercept Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Aflibercept: FDA labeling (2026-07-07, NDC 61755-005), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Aflibercept community threads and patient logs by age, biological sex, dosage, and treatment duration.